Workflow
长江投资(600119) - 2022 Q1 - 季度财报
Y.I.C.Y.I.C.(SH:600119)2022-04-28 16:00

Financial Performance - The company's operating revenue for Q1 2022 was ¥320,082,181.70, representing a year-on-year increase of 32.19%[5] - The net profit attributable to shareholders of the listed company was -¥4,482,170.21, indicating a non-applicable change[5] - The net cash flow from operating activities was -¥13,774,564.36, showing a non-applicable change[5] - Total operating revenue for Q1 2022 was CNY 320,082,181.70, an increase of 32.2% compared to CNY 242,144,003.02 in Q1 2021[21] - Net loss for Q1 2022 was CNY 7,021,472.45, compared to a net loss of CNY 664,030.83 in Q1 2021[22] - Operating profit for Q1 2022 was CNY -6,748,156.21, a decline from CNY -774,557.69 in Q1 2021[21] - The company reported a basic and diluted earnings per share of CNY -0.01 for Q1 2022, compared to CNY 0.00 in Q1 2021[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥799,819,972.65, a decrease of 1.38% compared to the end of the previous year[6] - As of March 31, 2022, the total assets of the company amounted to RMB 799,819,972.65, a decrease from RMB 811,014,493.41 at the end of 2021, reflecting a decline of approximately 1.5%[17] - The company's current assets totaled RMB 571,525,319.75, slightly up from RMB 568,583,301.78 at the end of 2021, indicating a marginal increase of about 0.3%[17] - The company's total liabilities stood at RMB 571,525,319.75, with short-term borrowings at RMB 170,478,444.43, which remained relatively stable compared to RMB 171,508,444.43 in the previous period[18] - Total liabilities as of Q1 2022 were CNY 436,153,009.06, slightly down from CNY 440,326,057.37 in the previous quarter[21] - Total equity attributable to shareholders was CNY 206,860,447.48, a decrease from CNY 211,342,617.69 in the previous quarter[21] Cash Flow - Cash flow from operating activities for Q1 2022 was CNY -13,774,564.36, compared to CNY -9,771,681.92 in Q1 2021[24] - The company’s cash inflow from operating activities was CNY 306,404,035.72, compared to CNY 169,518,593.62 in Q1 2021[24] - Cash flow from financing activities showed a net outflow of $9,439,494.81, compared to a net outflow of $11,639,659.15 in the previous period, reflecting improved cash management[25] - The company's cash and cash equivalents at the end of the period were $175,538,810.66, down from $194,434,697.73 at the beginning of the period[25] Research and Development - The company's research and development expenses decreased by 47.23% due to reduced personnel and investment in subsidiaries[11] - The company incurred research and development expenses of CNY 691,172.46 in Q1 2022, down from CNY 1,309,738.24 in Q1 2021[21] Investment Income - The company's investment income decreased by 79.52% primarily due to reduced dividends from associated companies[11] - Net cash flow from investment activities was $4,038,139.57, compared to $3,163,083.42 in the previous period, indicating a positive trend[25] - Total cash inflow from investment activities amounted to $45,214,583.80, while cash outflow was $41,176,444.23, resulting in a net inflow[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,248[13] Other Financial Metrics - The weighted average return on net assets was -2.14%, a decrease of 2.07 percentage points[6] - The company reported a significant decrease in non-operating income by 97.38% due to reduced penalty compensation received[11] - The company reported a significant increase in accounts payable, rising to RMB 111,224,678.18 from RMB 95,117,754.19, which is an increase of approximately 17%[18] - The company has a long-term investment of RMB 23,890,184.23, down from RMB 31,754,483.93, indicating a decrease of about 24.8%[18] - The company’s inventory was reported at RMB 42,159,275.78, showing a slight increase from RMB 41,038,902.94, which is an increase of approximately 2.7%[18] - The company has not disclosed any new product developments or market expansion strategies in the current report[15]